An exploratory study of intestinal flora combined with peripheral blood immune cell subsets to predict the therapeutic efficacy of PD-1 in patients with metastatic nasopharyngeal carcinoma

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100049503

Enrollment

Unknown

Registered

2021-08-02

Start date

2021-08-02

Completion date

Unknown

Last updated

2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nasopharyngeal carcinoma

Interventions

case series:No

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Pathologically confirmed metastatic nasopharyngeal carcinoma (stage IVb, 8th edition staging); 2. 18-65 years old, patients who can voluntarily eat orally; 3. Clinical evaluation to receive PD1 immunotherapy; 4. ECOG score 0-1 points; 5. Patients must be informed of the basic content of this study and sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Previous history of malignant tumor, except for fully treated basal cell carcinoma or squamous cell carcinoma and cervical carcinoma in situ; 2. Have received or plan to receive other types of immunotherapy such as PD-L1, CTLA-4, etc.; 3. Those who have received oral or intravenous antibiotics within 2 weeks before enrollment; 4. Patients with intestinal diseases such as Crohn's disease, ulcerative colitis, etc. who cannot defecate; 5. Pregnant or breastfeeding women, women without a pregnancy test (within 14 days prior to the first dose), and women who are pregnant.

Design outcomes

Primary

Measure	Time frame
diversity;	—

Countries

China

Contacts

Public ContactHuang Shuang

Zhejiang Cancer Hospital

huangshuang@zjcc.org.cn+86 18258111085

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026